IMMP Immutep Ltd

0.02 (1.02%)
Sep 22 2023 - Closed
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.


Draw Mode:

Volume 83,159
Bid Price 1.90
Ask Price 2.06
News -
Company Name Stock Ticker Symbol Market Type
Immutep Ltd IMMP NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
0.02 1.02% 1.99 20:00:00
Open Price Low Price High Price Close Price Prev Close
1.97 1.93 1.9874 1.98 1.97
Trades Volume VWAP Dollar Volume Avg Volume
408 83,159  1.96  163,374 -
Last Trade Time Type Quantity Stock Price Currency
17:43:54 89  1.94 USD

Immutep Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
2.36B 1.19B - 0 -39.9M 0.00 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News Immutep

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No IMMP Message Board. Create One! See More Posts on IMMP Message Board See More Message Board Posts

IMMP Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months0.
6 Months0.
1 Year0.
3 Years0.
5 Years0.

Immutep Ltd. is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's unique ability to stimulate or suppress the immune response. Immutep's lead clinical candidate, eftilagimod alpha ('efti'), is a soluble LAG-3 protein and first-in-class MHC Class II agonist that stimulates both innate and adaptive immunity to fight cancer.